Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults

Chengjie Xiong; Jingqin Luo; Suzanne E. Schindler; Anne M. Fagan; Tammie Benzinger; Jason Hassenstab; Joyce E. Balls-Berry; Folasade Agboola; Elizabeth Grant; Krista L. Moulder; John C. Morris

doi:10.1002/alz.12608

Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults

Chengjie Xiong, Jingqin Luo, Suzanne E. Schindler, Anne M. Fagan, Tammie Benzinger, Jason Hassenstab, Joyce E. Balls-Berry, Folasade Agboola, Elizabeth Grant, Krista L. Moulder, John C. Morris

Rochester, MN

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: Longitudinal changes in Alzheimer's disease (AD) biomarkers, including cerebrospinal fluid (CSF) analytes, amyloid uptakes from positron emission tomography (PET), structural outcomes from magnetic resonance imaging (MRI), and cognition, have not been compared between Blacks and Whites. Methods: A total of 179 Blacks and 1180 Whites who were cognitively normal at baseline and had longitudinal data from at least one biomarker modality were analyzed for the annual rates of change. Results: CSF amyloid beta (Aβ)42/Aβ40 declined more slowly (P =.0390), and amyloid (PET) accumulated more slowly (P =.0157), in Blacks than Whites. CSF Aβ42 changed in opposite directions over time between Blacks and Whites (P =.0039). The annual increase in CSF total tau and phosphorylated tau181 for Blacks was about half of that for Whites. Discussion: Longitudinal racial differences in amyloid biomarkers are observed. It will be important to comprehensively and prospectively examine the effects of apolipoprotein E genotype and sociocultural factors on these differences.

Original language	English (US)
Pages (from-to)	2570-2581
Number of pages	12
Journal	Alzheimer's and Dementia
Volume	18
Issue number	12
DOIs	https://doi.org/10.1002/alz.12608
State	Published - Dec 2022

Keywords

Alzheimer's disease
cerebrospinal fluid biomarkers
imaging biomarkers
longitudinal
racial difference

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Cellular and Molecular Neuroscience
Psychiatry and Mental health

Access to Document

10.1002/alz.12608

Cite this

@article{124cf26b36204728b255fd12bc2c0702,

title = "Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults",

abstract = "Introduction: Longitudinal changes in Alzheimer's disease (AD) biomarkers, including cerebrospinal fluid (CSF) analytes, amyloid uptakes from positron emission tomography (PET), structural outcomes from magnetic resonance imaging (MRI), and cognition, have not been compared between Blacks and Whites. Methods: A total of 179 Blacks and 1180 Whites who were cognitively normal at baseline and had longitudinal data from at least one biomarker modality were analyzed for the annual rates of change. Results: CSF amyloid beta (Aβ)42/Aβ40 declined more slowly (P =.0390), and amyloid (PET) accumulated more slowly (P =.0157), in Blacks than Whites. CSF Aβ42 changed in opposite directions over time between Blacks and Whites (P =.0039). The annual increase in CSF total tau and phosphorylated tau181 for Blacks was about half of that for Whites. Discussion: Longitudinal racial differences in amyloid biomarkers are observed. It will be important to comprehensively and prospectively examine the effects of apolipoprotein E genotype and sociocultural factors on these differences.",

keywords = "Alzheimer's disease, cerebrospinal fluid biomarkers, imaging biomarkers, longitudinal, racial difference",

author = "Chengjie Xiong and Jingqin Luo and Schindler, {Suzanne E.} and Fagan, {Anne M.} and Tammie Benzinger and Jason Hassenstab and Balls-Berry, {Joyce E.} and Folasade Agboola and Elizabeth Grant and Moulder, {Krista L.} and Morris, {John C.}",

note = "Publisher Copyright: {\textcopyright} 2022 the Alzheimer's Association.",

year = "2022",

month = dec,

doi = "10.1002/alz.12608",

language = "English (US)",

volume = "18",

pages = "2570--2581",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "12",

}

TY - JOUR

T1 - Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults

AU - Xiong, Chengjie

AU - Luo, Jingqin

AU - Schindler, Suzanne E.

AU - Fagan, Anne M.

AU - Benzinger, Tammie

AU - Hassenstab, Jason

AU - Balls-Berry, Joyce E.

AU - Agboola, Folasade

AU - Grant, Elizabeth

AU - Moulder, Krista L.

AU - Morris, John C.

PY - 2022/12

Y1 - 2022/12

N2 - Introduction: Longitudinal changes in Alzheimer's disease (AD) biomarkers, including cerebrospinal fluid (CSF) analytes, amyloid uptakes from positron emission tomography (PET), structural outcomes from magnetic resonance imaging (MRI), and cognition, have not been compared between Blacks and Whites. Methods: A total of 179 Blacks and 1180 Whites who were cognitively normal at baseline and had longitudinal data from at least one biomarker modality were analyzed for the annual rates of change. Results: CSF amyloid beta (Aβ)42/Aβ40 declined more slowly (P =.0390), and amyloid (PET) accumulated more slowly (P =.0157), in Blacks than Whites. CSF Aβ42 changed in opposite directions over time between Blacks and Whites (P =.0039). The annual increase in CSF total tau and phosphorylated tau181 for Blacks was about half of that for Whites. Discussion: Longitudinal racial differences in amyloid biomarkers are observed. It will be important to comprehensively and prospectively examine the effects of apolipoprotein E genotype and sociocultural factors on these differences.

AB - Introduction: Longitudinal changes in Alzheimer's disease (AD) biomarkers, including cerebrospinal fluid (CSF) analytes, amyloid uptakes from positron emission tomography (PET), structural outcomes from magnetic resonance imaging (MRI), and cognition, have not been compared between Blacks and Whites. Methods: A total of 179 Blacks and 1180 Whites who were cognitively normal at baseline and had longitudinal data from at least one biomarker modality were analyzed for the annual rates of change. Results: CSF amyloid beta (Aβ)42/Aβ40 declined more slowly (P =.0390), and amyloid (PET) accumulated more slowly (P =.0157), in Blacks than Whites. CSF Aβ42 changed in opposite directions over time between Blacks and Whites (P =.0039). The annual increase in CSF total tau and phosphorylated tau181 for Blacks was about half of that for Whites. Discussion: Longitudinal racial differences in amyloid biomarkers are observed. It will be important to comprehensively and prospectively examine the effects of apolipoprotein E genotype and sociocultural factors on these differences.

KW - Alzheimer's disease

KW - cerebrospinal fluid biomarkers

KW - imaging biomarkers

KW - longitudinal

KW - racial difference

UR - http://www.scopus.com/inward/record.url?scp=85125274038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125274038&partnerID=8YFLogxK

U2 - 10.1002/alz.12608

DO - 10.1002/alz.12608

M3 - Article

C2 - 35218143

AN - SCOPUS:85125274038

SN - 1552-5260

VL - 18

SP - 2570

EP - 2581

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 12

ER -

Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this